99 related articles for article (PubMed ID: 27100033)
21. Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position.
Winter E; Gozzi GJ; Chiaradia-Delatorre LD; Daflon-Yunes N; Terreux R; Gauthier C; Mascarello A; Leal PC; Cadena SM; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
Drug Des Devel Ther; 2014; 8():609-19. PubMed ID: 24920885
[TBL] [Abstract][Full Text] [Related]
22. Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators.
Kraege S; Köhler SC; Wiese M
ChemMedChem; 2016 Nov; 11(21):2422-2435. PubMed ID: 27735138
[TBL] [Abstract][Full Text] [Related]
23. Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation.
Boumendjel A; Macalou S; Valdameri G; Pozza A; Gauthier C; Arnaud O; Nicolle E; Magnard S; Falson P; Terreux R; Carrupt PA; Payen L; Di Pietro A
Curr Med Chem; 2011; 18(22):3387-401. PubMed ID: 21728961
[TBL] [Abstract][Full Text] [Related]
24. The More the Better-Investigation of Polymethoxylated
Stockmann P; Kuhnert L; Leinung W; Lakoma C; Scholz B; Paskas S; Mijatović S; Maksimović-Ivanić D; Honscha W; Hey-Hawkins E
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678870
[TBL] [Abstract][Full Text] [Related]
25. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
Antoni F; Bause M; Scholler M; Bauer S; Stark SA; Jackson SM; Manolaridis I; Locher KP; König B; Buschauer A; Bernhardt G
Eur J Med Chem; 2020 Apr; 191():112133. PubMed ID: 32105979
[TBL] [Abstract][Full Text] [Related]
26. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
27. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
28. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
Juvale K; Wiese M
Bioorg Med Chem Lett; 2012 Nov; 22(21):6766-9. PubMed ID: 23017888
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Kita DH; Guragossian N; Zattoni IF; Moure VR; Rego FGM; Lusvarghi S; Moulenat T; Belhani B; Picheth G; Bouacida S; Bouaziz Z; Marminon C; Berredjem M; Jose J; Gonçalves MB; Ambudkar SV; Valdameri G; Le Borgne M
Sci Rep; 2021 Jan; 11(1):1788. PubMed ID: 33469044
[TBL] [Abstract][Full Text] [Related]
30. Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.
Peña-Solórzano D; Scholler M; Bernhardt G; Buschauer A; König B; Ochoa-Puentes C
ACS Med Chem Lett; 2018 Aug; 9(8):854-859. PubMed ID: 30128080
[TBL] [Abstract][Full Text] [Related]
31. Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity.
Gallus J; Juvale K; Wiese M
Biochim Biophys Acta; 2014 Nov; 1838(11):2929-38. PubMed ID: 25128152
[TBL] [Abstract][Full Text] [Related]
32. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
[TBL] [Abstract][Full Text] [Related]
33. Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
Köhler SC; Silbermann K; Wiese M
Eur J Med Chem; 2016 Nov; 124():881-895. PubMed ID: 27676469
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the Fluorescence Properties of 4-Dialkylaminochalcones and Investigation of the Cytotoxic Mechanism of Chalcones.
Zhou B; Jiang P; Lu J; Xing C
Arch Pharm (Weinheim); 2016 Jul; 349(7):539-52. PubMed ID: 27214789
[TBL] [Abstract][Full Text] [Related]
35. Theoretical insight into the multiple interactions of quinazoline inhibitors with breast cancer resistance protein (BCRP/ABCG2).
Li WJ; Chen XH; Zeng JC; Duan LL; Liu ZH; Sheng XH
J Biomol Struct Dyn; 2020 Sep; 38(14):4336-4343. PubMed ID: 31594454
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of KO143, an ABCG2 inhibitor.
Liu K; Zhu J; Huang Y; Li C; Lu J; Sachar M; Li S; Ma X
Drug Metab Pharmacokinet; 2017 Aug; 32(4):193-200. PubMed ID: 28619281
[TBL] [Abstract][Full Text] [Related]
37. Carborane-Based ABCG2-Inhibitors Sensitize ABC-(Over)Expressing Cancer Cell Lines for Doxorubicin and Cisplatin.
Paskas S; Stockmann P; Mijatović S; Kuhnert L; Honscha W; Hey-Hawkins E; Maksimović-Ivanić D
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004447
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and bioevaluation of substituted chalcones, coumaranones and other flavonoids as anti-HIV agents.
Cole AL; Hossain S; Cole AM; Phanstiel O
Bioorg Med Chem; 2016 Jun; 24(12):2768-76. PubMed ID: 27161874
[TBL] [Abstract][Full Text] [Related]
39. The Quinazoline-Chalcone and Quinazolinone-Chalcone Hybrids: A Promising Combination for Biological Activity.
Mass EB; Duarte GV; Russowsky D
Mini Rev Med Chem; 2021; 21(2):186-203. PubMed ID: 32744973
[TBL] [Abstract][Full Text] [Related]
40. Structurally Diverse Cytotoxic Dimeric Chalcones from Oxytropis chiliophylla.
Liu Y; Zhang X; Kelsang N; Tu G; Kong D; Lu J; Zhang Y; Liang H; Tu P; Zhang Q
J Nat Prod; 2018 Feb; 81(2):307-315. PubMed ID: 29400468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]